Compare DexCom, Inc. (DXCM) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Tenet Healthcare Corporation — how do they compare? DexCom, Inc. trades at $84.46 (market cap $31.81B), while Tenet Healthcare Corporation trades at $260 (market cap $20.92B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Tenet Healthcare Corporation is more actively traded (455,764 versus 2,861,821). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Tenet Healthcare Corporation for 15 Days on average.
| DXCM | THC | |
|---|---|---|
Market Cap | $31.81B | $20.92B |
Volume | 2,861,821 | 455,764 |
Sector | Health | Health |
52-Week High | $92.34 | $280.77 |
52-Week Low | $54.84 | $161.37 |
Typical Hold Time | 62 Days | 15 Days |
Enterprise Value | $31.26B | $32.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 82.83% gross margins, and 53.31% ROE. Recent news highlights strong cash flow supporting capital returns, with Q3 2026 results expected October 29, 2026.
THC presents compelling value with a 10.04 P/E ratio and 81.25% analyst buy ratings. Upside potential to $283.36 consensus target exists, though negative cash flow trends and insider selling warrant monitoring. The stock's premium valuation (P/B 4.49) requires sustained execution amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
